196 related articles for article (PubMed ID: 37082121)
1. Dyslipidemia and serum cystatin C levels as biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus.
Dejenie TA; Abebe EC; Mengstie MA; Seid MA; Gebeyehu NA; Adella GA; Kassie GA; Gebrekidan AY; Gesese MM; Tegegne KD; Anley DT; Feleke SF; Zemene MA; Dessie AM; Moges N; Kebede YS; Bantie B; Adugna DG
Front Endocrinol (Lausanne); 2023; 14():1124367. PubMed ID: 37082121
[TBL] [Abstract][Full Text] [Related]
2. Triglyceride-glucose index: A surrogate marker of homeostasis model assessment of insulin resistance to predict diabetic nephropathy.
Khan S; Qayyum S; Khan MNA
J Pak Med Assoc; 2024 May; 74(5):862-867. PubMed ID: 38783431
[TBL] [Abstract][Full Text] [Related]
3. Identification and Stratification of Diabetic Kidney Disease Using Serum Cystatin C and Serum Creatinine Based Estimating Equations in Type 2 Diabetes: A Comparative Analysis.
Avinash S; Singh VP; Agarwal AK; Chatterjee S; Araya V
J Assoc Physicians India; 2015 Nov; 63(11):28-35. PubMed ID: 29900708
[TBL] [Abstract][Full Text] [Related]
4. Utility of urinary biomarkers as a diagnostic tool for early diabetic nephropathy in patients with type 2 diabetes mellitus.
Vijay S; Hamide A; Senthilkumar GP; Mehalingam V
Diabetes Metab Syndr; 2018 Sep; 12(5):649-652. PubMed ID: 29673928
[TBL] [Abstract][Full Text] [Related]
5. Glycemic control, dyslipidemia and endothelial dysfunction in coexisted diabetes, hypertension and nephropathy.
Shahid SM; Nawab SN; Shaikh R; Mahboob T
Pak J Pharm Sci; 2012 Jan; 25(1):123-9. PubMed ID: 22186319
[TBL] [Abstract][Full Text] [Related]
6. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.
Jeon YK; Kim MR; Huh JE; Mok JY; Song SH; Kim SS; Kim BH; Lee SH; Kim YK; Kim IJ
J Korean Med Sci; 2011 Feb; 26(2):258-63. PubMed ID: 21286018
[TBL] [Abstract][Full Text] [Related]
7. Relationship between periodontal status and dyslipidemia in patients with type 2 diabetic nephropathy and chronic periodontitis: A cross-sectional study.
Zhang D; Zhao C; Liu Z; Ding Y; Li W; Yang H; Wang Z; Li Y
J Periodontal Res; 2022 Oct; 57(5):969-976. PubMed ID: 35848007
[TBL] [Abstract][Full Text] [Related]
8. [Myocardial dysfunction, neuropathy and nephropathy in long standing type 1 diabetic patients].
Galicka-Latała D; Konduracka E; Kuźniewski M; Fedak D; Sieradzki J
Przegl Lek; 2005; 62(12):1451-4. PubMed ID: 16786771
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of triglyceride and cystatin C ratio in diabetic kidney disease: a retrospective and prospective cohort study based on renal biopsy.
Wei J; Wang B; Shen FJ; Zhang TT; Duan Z; Zhou DM
BMC Nephrol; 2022 Jul; 23(1):270. PubMed ID: 35896961
[TBL] [Abstract][Full Text] [Related]
10. Serum cystatin C as an indicator for early detection of diabetic nephropathy in type 2 diabetes mellitus.
Elsayed MS; El Badawy A; Ahmed A; Omar R; Mohamed A
Diabetes Metab Syndr; 2019; 13(1):374-381. PubMed ID: 30641728
[TBL] [Abstract][Full Text] [Related]
11. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of dyslipidemia associated with complications in diabetic patients: a nationwide study in Thailand.
Narindrarangkura P; Bosl W; Rangsin R; Hatthachote P
Lipids Health Dis; 2019 Apr; 18(1):90. PubMed ID: 30954084
[TBL] [Abstract][Full Text] [Related]
13. Higher serum betatrophin level in type 2 diabetes subjects is associated with urinary albumin excretion and renal function.
Chen CC; Susanto H; Chuang WH; Liu TY; Wang CH
Cardiovasc Diabetol; 2016 Jan; 15():3. PubMed ID: 26739836
[TBL] [Abstract][Full Text] [Related]
14. Cystatin C and cystatin glomerular filtration rate as markers of early renal disease in Asian Indian subjects with glucose intolerance (CURES-32).
Surendar J; Anuradha S; Ashley B; Balasubramanyam M; Aravindhan V; Rema M; Mohan V
Metab Syndr Relat Disord; 2009 Oct; 7(5):419-25. PubMed ID: 19419268
[TBL] [Abstract][Full Text] [Related]
15. Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy.
Christensson AG; Grubb AO; Nilsson JA; Norrgren K; Sterner G; Sundkvist G
J Intern Med; 2004 Dec; 256(6):510-8. PubMed ID: 15554952
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of early biomarkers of renal dysfunction in diabetic patients.
Al-Hazmi SF; Gad HGM; Alamoudi AA; Eldakhakhny BM; Binmahfooz SK; Alhozali AM
Saudi Med J; 2020 Jul; 41(7):690-697. PubMed ID: 32601635
[TBL] [Abstract][Full Text] [Related]
17. Cystatin-C and TGF-β levels in patients with diabetic nephropathy.
Takir M; Unal AD; Kostek O; Bayraktar N; Demirag NG
Nefrologia; 2016; 36(6):653-659. PubMed ID: 27745866
[TBL] [Abstract][Full Text] [Related]
18. Dyslipidemia in diabetic kidney disease classified by proteinuria and renal dysfunction: A cross-sectional study from a regional diabetes cohort.
Hirano T; Satoh N; Kodera R; Hirashima T; Suzuki N; Aoki E; Oshima T; Hosoya M; Fujita M; Hayashi T; Ito Y
J Diabetes Investig; 2022 Apr; 13(4):657-667. PubMed ID: 34665936
[TBL] [Abstract][Full Text] [Related]
19. Urinary Cyclophilin A and serum Cystatin C as biomarkers for diabetic nephropathy in children with type 1 diabetes.
Salem NA; El Helaly RM; Ali IM; Ebrahim HAA; Alayooti MM; El Domiaty HA; Aboelenin HM
Pediatr Diabetes; 2020 Aug; 21(5):846-855. PubMed ID: 32304131
[TBL] [Abstract][Full Text] [Related]
20. Growth arrest-specific protein 6 (Gas6) as a noninvasive biomarker for early detection of diabetic nephropathy.
Li W; Wang J; Ge L; Shan J; Zhang C; Liu J
Clin Exp Hypertens; 2017; 39(4):382-387. PubMed ID: 28513288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
